India could soon get a lot thinner - at least in theory. The expiration of the patent on semaglutide, the molecule behind Danish drugmaker Novo Nordisk's blockbuster weight-loss drugs Wegovy and Ozempic, is set to reshape the landscape of obesity treatment. This will enable domestic pharmaceutical firms to introduce cheaper generics, potentially slashing prices over 50% and making these treatments accessible to a broader population.
Investment bank Jefferies forecasts that the semaglutide market could balloon to $1 billion domestically, given the right pricing strategies and uptake. With expectations of around 50 branded generics entering the market shortly after the patent expiration, India’s robust pharmaceutical industry could follow the familiar pattern seen previously with other medications.
Currently, the price for Ozempic ranges from 8,800 to 11,000 rupees ($95-$119), while Wegovy is priced between 10,000 and 16,000 rupees ($108-$173). With generics, these costs are projected to drop to approximately 3,000 to 5,000 rupees ($36-$54) per month, significantly improving access for many.
Given that India is home to over 77 million individuals with type 2 diabetes and a large population classified as overweight, the arrival of affordable GLP-1 drugs could provide healthcare professionals with new tools to combat these growing health issues.
However, doctors caution about the potential misuse of these drugs as accessibility increases. Reports suggest exercising caution during this transition, particularly in regulating the quality of generics that will enter the market, as there’s a heightened risk of substandard medications damaging the reputation of the drug class.
The Indian government has already issued advisories against direct consumer promotion of prescription weight-loss drugs, advocating for administration under medical guidance only. As the drug landscape changes, the balance between affordability and regulation will be closely monitored to ensure patient safety and credibility in treatment outcomes.
Investment bank Jefferies forecasts that the semaglutide market could balloon to $1 billion domestically, given the right pricing strategies and uptake. With expectations of around 50 branded generics entering the market shortly after the patent expiration, India’s robust pharmaceutical industry could follow the familiar pattern seen previously with other medications.
Currently, the price for Ozempic ranges from 8,800 to 11,000 rupees ($95-$119), while Wegovy is priced between 10,000 and 16,000 rupees ($108-$173). With generics, these costs are projected to drop to approximately 3,000 to 5,000 rupees ($36-$54) per month, significantly improving access for many.
Given that India is home to over 77 million individuals with type 2 diabetes and a large population classified as overweight, the arrival of affordable GLP-1 drugs could provide healthcare professionals with new tools to combat these growing health issues.
However, doctors caution about the potential misuse of these drugs as accessibility increases. Reports suggest exercising caution during this transition, particularly in regulating the quality of generics that will enter the market, as there’s a heightened risk of substandard medications damaging the reputation of the drug class.
The Indian government has already issued advisories against direct consumer promotion of prescription weight-loss drugs, advocating for administration under medical guidance only. As the drug landscape changes, the balance between affordability and regulation will be closely monitored to ensure patient safety and credibility in treatment outcomes.
